The LPA-Aspirin Genotype Test - Guiding Personalized Therapy
Research indicates that LPA genotyping predicts cardiovascular disease (CVD) risk and event reduction during aspirin therapy.*  

The LPA-Aspirin genotype test can provide information in addition to traditional risk factors to help with the identification of patients at increased risk for CVD events and the personalization of their treatment.



What is the LPA-Aspirin Genotype Test?
LPA 4399Met carriers have been shown to have approximately two-fold higher risk of CVD events than noncarriers in case-control and prospective studies.  In addition, aspirin therapy was found to reduce events more effectively in LPA carriers than in noncarriers in the Women's Health Study.

The information provided by LPA genotyping may help clinicians assess the potential cardiovascular benefit of aspirin as compared to the bleeding risk and reduce risk through personalized therapy. 


Who We Are
We understand that every patient is unique and customized therapy is often necessary.  To address this need, we offer sophisticated risk insights from Berkeley HeartLab test results to help clinicians reduce risk and prevent the progression of cardiovascular disease.

In The News
Apr 29, 2009
Celera Presents Results Showing That Carriers of an LPA Gene Variant are at Elevated Risk of CHD Among Non-users of Aspirin, but not Among Aspirin Users

*Study populations predominantly consisted of Caucasian men and women 45-70 years of age.